Literature DB >> 19831502

Characterization of the interaction between liposomal formulations and Pseudomonas aeruginosa.

Yimei Jia1, Hélène Joly, Abdelwahab Omri.   

Abstract

The interactions between three liposomal formulations and Pseudomonas aeruginosa cells were evaluated by a lipid mixing assay and electron paramagnetic resonance (EPR) spectroscopy. The effect of the bacteria on the liposomal phase characteristics, the release of the liposomes' content, and the uptake rate of gentamicin by bacteria were monitored as a function of time, using EPR spectroscopy. The [16-DSA uptake](Total) from DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) liposomes reached 93 +/- 12% over a 3-hour assay period, of which 9% crossed the bacterial inner membrane. A small amount of 16-DSA uptake from DPPC/Chol (cholesterol) vesicles was found throughout the 3-hour period of time. Although DPPC/DMPG (dimyristoylphosphatidylglycerol) vesicles showed a smaller value of [16-DSA uptake](Total) with respect to that of DPPC vesicles, they appeared to be effective in disrupting the bacterial membrane, resulting in a greater accumulation of 16-DSA inside the inner membrane. Exposure to bacteria caused the DPPC/Chol, DPPC, and DPPC/DMPG formulations to release 4.6 +/- 1.5, 17.6 +/- 1.2, and 34 +/- 3.7% of their content, respectively. Time-dependent fluid regions were developed within the vesicles when mixed with bacteria, and their growth over time depended on liposomal formulations. Incubation of gentamicin with bacteria for 3 hours resulted in 87 +/- 3% of the drug crossing the bacterial inner membrane. In conclusion, interaction between the liposome drug carriers and the bacterial cells result in vesicle fusion, disruption of the bacterial membrane, release of the liposomal content in the close vicinity of the bacteria cells, and the subsequent intracellular uptake of the released liposomal content.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19831502     DOI: 10.3109/08982100903218892

Source DB:  PubMed          Journal:  J Liposome Res        ISSN: 0898-2104            Impact factor:   3.648


  7 in total

1.  Advances in antimicrobial photodynamic inactivation at the nanoscale.

Authors:  Nasim Kashef; Ying-Ying Huang; Michael R Hamblin
Journal:  Nanophotonics       Date:  2017-08-01       Impact factor: 8.449

Review 2.  All you need is light: antimicrobial photoinactivation as an evolving and emerging discovery strategy against infectious disease.

Authors:  Tyler G St Denis; Tianhong Dai; Leonid Izikson; Christos Astrakas; Richard Rox Anderson; Michael R Hamblin; George P Tegos
Journal:  Virulence       Date:  2011-11-01       Impact factor: 5.882

3.  Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia.

Authors:  Hui Xin Ong; Daniela Traini; David Cipolla; Igor Gonda; Mary Bebawy; Helen Agus; Paul M Young
Journal:  Pharm Res       Date:  2012-07-26       Impact factor: 4.200

4.  Effective Treatment of Mycobacterium avium subsp. hominissuis and Mycobacterium abscessus Species Infections in Macrophages, Biofilm, and Mice by Using Liposomal Ciprofloxacin.

Authors:  James D Blanchard; Valerie Elias; David Cipolla; Igor Gonda; Luiz E Bermudez
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

5.  Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform.

Authors:  Tianhong Dai; Beth B Fuchs; Jeffrey J Coleman; Renato A Prates; Christos Astrakas; Tyler G St Denis; Martha S Ribeiro; Eleftherios Mylonakis; Michael R Hamblin; George P Tegos
Journal:  Front Microbiol       Date:  2012-04-10       Impact factor: 5.640

Review 6.  Novel nanomaterial-based antibacterial photodynamic therapies to combat oral bacterial biofilms and infectious diseases.

Authors:  Manlin Qi; Minghan Chi; Xiaolin Sun; Xianju Xie; Michael D Weir; Thomas W Oates; Yanmin Zhou; Lin Wang; Yuxing Bai; Hockin Hk Xu
Journal:  Int J Nanomedicine       Date:  2019-08-28

7.  The Impact of an Efflux Pump Inhibitor on the Activity of Free and Liposomal Antibiotics against Pseudomonas aeruginosa.

Authors:  Douweh Leyla Gbian; Abdelwahab Omri
Journal:  Pharmaceutics       Date:  2021-04-18       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.